Aricept
$ 54,00 – $ 264,00Price range: $ 54,00 through $ 264,00
Aristocort
$ 67,00 – $ 602,00Price range: $ 67,00 through $ 602,00
Arimidex
$ 194,00 – $ 441,00Price range: $ 194,00 through $ 441,00
Arimidex is a potent non-steroidal aromatase inhibitor designed to lower estrogen levels in postmenopausal women. It is primarily indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in women who have completed menopause. The medication is also utilized as a first-line therapy for postmenopausal patients with locally advanced or metastatic breast cancer. By effectively blocking the aromatase enzyme, this treatment helps reduce the production of estrogen that can stimulate the growth of certain tumor types. This targeted approach provides a critical therapeutic option for managing hormone-sensitive conditions and improving long-term health outcomes.
Active substance: Anastrozole
SKU:
Arimidex
Category: Cancer
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Arimidex belongs to a class of targeted endocrine medications known as nonsteroidal aromatase inhibitors. In the United States, it is approved by the Food and Drug Administration (FDA) as a prescription-only therapy intended primarily for postmenopausal women facing specific stages of hormone receptor-positive breast cancer.
Understanding how this medication interacts with hormonal pathways helps set realistic expectations during therapy. While it serves as a cornerstone in adjuvant and advanced oncology protocols, balanced medical supervision remains essential to navigate both its therapeutic benefits and potential bone or lipid profile adjustments.
Clinical Overview and Pharmacological Profile
Main uses
Arimidex is indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also prescribed for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer, as well as for second-line treatment of advanced breast cancer in patients whose disease has progressed following tamoxifen therapy. Any application outside FDA-approved postmenopausal breast cancer indications–such as off-label use in male gynecomastia or premenopausal hormonal management–is considered off-label and must be evaluated strictly on an individual basis by a qualified provider.
How the drug works
In postmenopausal individuals, circulating estrogen is primarily produced through the enzymatic conversion of adrenal androgens (androstenedione and testosterone) into estrone and estradiol by aromatase in peripheral tissues. Arimidex selectively and reversibly binds to the aromatase enzyme, inhibiting this conversion process. Daily administration reduces serum estradiol concentrations by approximately 80%, depriving estrogen-dependent breast tumor cells of the growth signals required for proliferation. It exhibits no significant direct estrogenic, androgenic, or progestational activity, nor does it alter adrenal corticosteroid or aldosterone secretion.
What happens in the body
Following oral administration, anastrozole is absorbed rapidly, reaching peak plasma concentrations within 2 hours under fasting conditions. Food slightly decreases the rate of absorption but does not meaningfully alter the overall extent of absorption. The plasma elimination half-life is approximately 50 hours, which supports steady once-daily administration. Steady-state plasma concentrations are typically achieved after 7 consecutive days of daily dosing. Hepatic metabolism accounts for the primary clearance pathway via N-dealkylation, hydroxylation, and glucuronidation, followed by renal and biliary excretion of inactive metabolites and a small fraction of unchanged drug.
Dosing schedule
The standard FDA-approved dosage for adult postmenopausal patients is one 1 mg tablet taken orally once daily. Tablets should be swallowed whole with fluid and may be taken with or without food at the same time each day to maintain consistent blood levels. In the early breast cancer adjuvant setting, the established treatment duration frequently extends up to 5 years, depending on individual recurrence risk and tolerance. Clinical studies indicate that dosage adjustments are not required for elderly patients or those with mild-to-moderate hepatic or renal impairment.
Compatibility with other medicines
Tamoxifen should not be co-administered with Arimidex. Clinical trial evidence demonstrates that tamoxifen reduces the plasma concentration of anastrozole by approximately 27% and does not offer incremental efficacy over single-agent therapy. Furthermore, estrogen-containing agents–including systemic hormone replacement therapies, oral contraceptives, or topical estrogen preparations–directly counteract the pharmacological mechanism of action of Arimidex and must be avoided during therapy.
Safety Guidelines, Patient Information, and FAQs
What side effects may occur
On one hand, Arimidex offers a targeted approach without the classic toxicities of systemic cytotoxic chemotherapy; on the other hand, profound estrogen depletion produces a distinct spectrum of side effects. Frequently reported adverse events include vasomotor symptoms (hot flashes), musculoskeletal pain (arthralgia, back pain, joint stiffness), fatigue, asthenia, nausea, headache, and skin rash. Long-term estrogen suppression also increases the rate of bone mineral density loss, which can lead to osteopenia, osteoporosis, and bone fractures. Mild elevations in serum cholesterol and liver enzymes have also been observed during routine blood monitoring.
Important precautions
Because suppression of circulating estrogen reduces bone mineral density, baseline dual-energy X-ray absorptiometry (DEXA) scans are recommended prior to initiating treatment, alongside routine monitoring during ongoing therapy. Patients with pre-existing ischemic heart disease require careful clinical management, as clinical trials indicated a slightly higher incidence of ischemic cardiovascular events compared to tamoxifen. Arimidex can cause fetal harm when administered to a pregnant female and is strictly contraindicated during pregnancy or lactation. It is not indicated for premenopausal women.
What to avoid while taking it
Patients should exercise caution regarding dietary supplements containing high amounts of phytoestrogens (such as concentrated soy isoflavones, red clover, or black cohosh), as these compounds may exhibit weak estrogenic effects that interfere with aromatase inhibition. Moderate alcohol intake does not directly alter anastrozole clearance, but chronic high-volume alcohol consumption can compound bone density loss and place additional metabolic stress on the liver.
First days of treatment
Therapeutic hormonal suppression occurs at the cellular level within the first week of daily administration, though patients may not immediately notice physical changes. Mild vasomotor reactions (such as sudden warmth or flushing) or subtle joint discomfort may begin during the initial weeks of treatment. Keeping a daily symptom diary during early therapy helps facilitate constructive follow-up discussions with your clinical care team.
If you skip a dose
If a dose is missed, take the missed tablet as soon as remembered on that day. However, if it is almost time for the next scheduled dose, skip the missed tablet and resume the regular daily schedule. Patients must never take two tablets at the same time to make up for a missed dose. Maintaining an uninterrupted once-daily regimen ensures consistent enzyme inhibition.
Storage and expiration
Store at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F) in accordance with US Pharmacopeia guidelines. Keep the container tightly closed to protect the medication from excessive moisture, heat, and direct light. Store safely out of reach of children and domestic pets. Do not use tablets past the expiration date stamped on the packaging.
| Parameter | Clinical Detail |
|---|---|
| Active Ingredient | Anastrozole (1 mg per tablet) |
| Therapeutic Class | Nonsteroidal Aromatase Inhibitor |
| Prescription Status | Rx only (Prescription required under US federal law) |
| Route of Administration | Oral |
| Elimination Half-Life | Approximately 50 hours |
| Primary Purpose | Estrogen-suppressive oncology therapy in postmenopausal women |
| Primary Safety Monitor | Bone mineral density (DEXA scans) & lipid profiles |
How long is adjuvant Arimidex treatment typically continued?
In postmenopausal women with early-stage hormone receptor-positive breast cancer, standard adjuvant therapy is typically prescribed for a duration of 5 years. However, exact duration depends on individual disease stage, overall tolerance, and ongoing risk assessment conducted by the attending oncologist.
Why is Arimidex contraindicated in premenopausal women?
In premenopausal individuals, functioning ovaries produce large amounts of estrogen through feedback loops controlled by the pituitary gland. Inhibiting peripheral aromatase in premenopausal women does not reliably suppress ovarian estrogen output and can reflexively stimulate gonadotropin secretion, rendering the treatment ineffective and potentially hazardous.
Can joint pain from Arimidex be safely managed?
Musculoskeletal stiffness and arthralgia are common secondary effects of low estrogen levels. Healthcare providers often recommend weight-bearing physical activity, adequate vitamin D and calcium supplementation, or mild over-the-counter analgesics. Any management plan for persistent joint symptoms should be coordinated with your prescribing physician.
What cardiovascular precautions should be taken during therapy?
Patients with a prior history of ischemic heart disease or elevated cardiovascular risk factors should inform their healthcare provider before starting treatment. Routine monitoring of lipid levels (cholesterol) and prompt evaluation of cardiac symptoms, such as chest tightness or shortness of breath, are essential elements of comprehensive care.
Dispensed in accordance with applicable federal and state regulations upon presentation of a valid prescription.
This text is for informational purposes only and does not constitute individual medical advice.
Additional information
| Dosage |
1mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills |
| Ενεργός Ουσία |
Related products
Aromasin
$ 123,00 – $ 1 152,00Price range: $ 123,00 through $ 1 152,00
Active substance: Exemestane
More Details
This product has multiple variants. The options may be chosen on the product page
Casodex
$ 50,00 – $ 1 440,00Price range: $ 50,00 through $ 1 440,00
Active substance: bicalutamide
More Details
This product has multiple variants. The options may be chosen on the product page
Cytoxan
$ 51,00 – $ 420,00Price range: $ 51,00 through $ 420,00
Active substance: Cyclophosphamide
More Details
This product has multiple variants. The options may be chosen on the product page
Evista
$ 50,00 – $ 361,00Price range: $ 50,00 through $ 361,00
Active substance: Raloxifene
More Details
This product has multiple variants. The options may be chosen on the product page
Hydrea
$ 64,00 – $ 541,00Price range: $ 64,00 through $ 541,00
Active substance: Hydroxyurea
More Details
This product has multiple variants. The options may be chosen on the product page
LDN
$ 81,00 – $ 266,00Price range: $ 81,00 through $ 266,00
Active substance: Naltrexone
More Details
This product has multiple variants. The options may be chosen on the product page
Triamcinolone
$ 45,00 – $ 289,00Price range: $ 45,00 through $ 289,00
Active substance: Triamcinolone
More Details
This product has multiple variants. The options may be chosen on the product page
Zofran
$ 44,00 – $ 258,00Price range: $ 44,00 through $ 258,00
Active substance: Ondansetron
More Details
This product has multiple variants. The options may be chosen on the product page
